Legal & General Group
CLSD

Legal & General Group’s Clearside Biomedical CLSD Stock Holding History

Legal & General Group’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-278
Closed -$4K – 3361
2019
Q2 		$4K Hold
278
– – ﹤0.01% 3457
2019
Q1 		$6K Hold
278
– – ﹤0.01% 3299
2018
Q4 		$4K Hold
278
– – ﹤0.01% 3349
2018
Q3 		$26K Hold
278
– – ﹤0.01% 3100
2018
Q2 		$45K Buy
278
+29
+12% +$4.89K ﹤0.01% 2796
2018
Q1 		$40K Buy
249
+46
+23% +$5.6K ﹤0.01% 2851
2017
Q4 		$21K Hold
203
– – ﹤0.01% 3135
2017
Q3 		$27K Hold
203
– – ﹤0.01% 3085
2017
Q2 		$28K Buy
203
+151
+290% +$18.1K ﹤0.01% 3058
2017
Q1 		$6K Hold
52
– – ﹤0.01% 3230
2016
Q4 		$7K Buy
+52
New +$13.1K ﹤0.01% 3261

Other funds holding CLSD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Legal & General Group's CLSD Position: Q3 2019 in Review

Legal & General Group sold out of Clearside Biomedical (CLSD) in Q3 2019, closing a stake of 278 shares — an estimated $4K sold.

Legal & General Group first reported a position in CLSD in Q4 2016 and held it in 11 quarters. The position peaked at $45K in Q2 2018. 34 funds tracked by Wall St. Rank hold CLSD as of Q3 2019.

  • Legal & General Group reported no remaining Clearside Biomedical position as of Q3 2019 after selling out during the quarter.
  • Legal & General Group sold 278 Clearside Biomedical shares in Q3 2019, an estimated $4K.
  • Legal & General Group first reported a position in Clearside Biomedical in Q4 2016 and held it in 11 quarters.
  • Legal & General Group's Clearside Biomedical position peaked at $45K in Q2 2018.
  • 34 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2019.

Based on Legal & General Group's 13F filing for Q3 2019, filed 13 Nov 2019.